The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance

#2101

Introduction: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system.

Aim(s): As there is no in vitro data on TMZ sensitivity in PNETs, our aim was to determine TMZ sensitivity in PNET cell lines and to determine the effect of TMZ exposure on chemosensitivity and expression of MGMT and MRR components.

Materials and methods: Two PNET cell lines, BON-1 and QGP-1, were used to determine TMZ sensitivity. TMZ resistance was induced by exposing cells to three 24-hour challenges with increasing doses of TMZ, each followed by a two week drug-free period. Cell growth, mRNA expression of MGMT and MMR components, apoptosis induction and cell cycle were assessed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Blazevic A

Authors: Blazevic A, Dogan-Oruc F, Dedeci M, Van Koetsveld P, Feelders R,

Keywords: Pancreatic neuroendocrine tumors, Temozolomide, Cell lines, Tumor growth, O6-methylguanine-DNA methyltransferase (MGMT), Mismatch repair (MMR) system,